ACTB and colorectal carcinoma: FMTDNAT-Cologuard was designed to detect human hemoglobin (i.e., like FIT) plus detection of mutations associated with CRC in the DNA of cells shed by advanced adenomas or CRC (quantitative molecular assays for KRAS mutations, aberrant NDRG4 and BMP3 methylation, and β-actin, plus a hemoglobin immunoassay) [7,20].